Genexine, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported negative sales was KRW 0.00029 million compared to sales of KRW 2.76 million a year ago. Net loss was KRW 24,614.17 million compared to KRW 15,220.04 million a year ago. Basic loss per share from continuing operations was KRW 603 compared to KRW 466.1538 a year ago. Diluted loss per share from continuing operations was KRW 603 compared to KRW 466.1538 a year ago. Basic loss per share was KRW 603 compared to KRW 606 a year ago.
For the six months, sales was KRW 7 million compared to KRW 4.72 million a year ago. Net loss was KRW 48,527.97 million compared to net income of KRW 1,179.36 million a year ago. Basic loss per share from continuing operations was KRW 1,227 compared to basic earnings per share from continuing operations of KRW 36.1538 a year ago. Diluted loss per share from continuing operations was KRW 1,227 compared to diluted earnings per share from continuing operations of KRW 36.1538 a year ago. Basic loss per share was KRW 1,227 compared to basic earnings per share of KRW 47 a year ago.